(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Aspen Group, Phio Pharmaceuticals Corp., and Groupon.

The three biggest losers today are Qutoutiao, Predictive Oncology, and Qurate Retail.

Winners today

1. Aspen Group (ASPU) – 117.56%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group rising 117.56% to $0.15 on Wednesday, after two sequential sessions in a row of gains. NASDAQ jumped 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 9.9%, now sitting on 74.29M for the twelve trailing months.

Moving Average

Aspen Group’s worth is way above its 50-day moving average of $0.10 and way below its 200-day moving average of $0.35.

Volatility

Aspen Group’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.76%, a negative 0.12%, and a positive 9.74%.

Aspen Group’s highest amplitude of average volatility was 10.24% (last week), 8.87% (last month), and 9.74% (last quarter).

More news about Aspen Group.

2. Phio Pharmaceuticals Corp. (PHIO) – 21.73%

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

NASDAQ ended the session with Phio Pharmaceuticals Corp. rising 21.73% to $4.09 on Wednesday while NASDAQ rose 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Phio Pharmaceuticals Corp. has a trailing twelve months EPS of $-9.72.

Volume

Today’s last reported volume for Phio Pharmaceuticals Corp. is 8795600 which is 7113.94% above its average volume of 121925.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Phio Pharmaceuticals Corp.’s EBITDA is 3.37.

More news about Phio Pharmaceuticals Corp..

3. Groupon (GRPN) – 17.68%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon jumping 17.68% to $3.50 on Wednesday while NASDAQ rose 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-7.03.

More news about Groupon.

4. Soleno Therapeutics (SLNO) – 10.13%

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

NASDAQ ended the session with Soleno Therapeutics jumping 10.13% to $4.35 on Wednesday while NASDAQ rose 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Soleno Therapeutics has a trailing twelve months EPS of $-2.84.

More news about Soleno Therapeutics.

5. Seanergy Maritime Holdings Corp (SHIPW) – 10%

NASDAQ ended the session with Seanergy Maritime Holdings Corp jumping 10% to $0.03 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ rose 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around up trend trading session today.

PE Ratio

Seanergy Maritime Holdings Corp has a trailing twelve months price to earnings ratio of 0.21. Meaning, the purchaser of the share is investing $0.21 for every dollar of annual earnings.

Yearly Top and Bottom Value

Seanergy Maritime Holdings Corp’s stock is valued at $0.03 at 17:32 EST, below its 52-week high of $0.03 and higher than its 52-week low of $0.03.

More news about Seanergy Maritime Holdings Corp.

6. Sabre Corporation (SABR) – 9.72%

Sabre Corporation, through its subsidiaries, provides software and technology solutions for the travel industry worldwide. It operates in two segments, Travel Solutions and Hospitality Solutions. The Travel Solutions segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments. This segment also provides a portfolio of software technology products and solutions through software-as-a-service (SaaS) and hosted delivery models to airlines and other travel suppliers. Its products include reservation systems for carriers, commercial and operations products, agency solutions, and data-driven intelligence solutions. The Hospitality Solutions segment provides software and solutions to hoteliers through SaaS and hosted delivery models. Sabre Corporation was incorporated in 2006 and is headquartered in Southlake, Texas.

NASDAQ ended the session with Sabre Corporation jumping 9.72% to $3.56 on Wednesday, following the last session’s downward trend. NASDAQ jumped 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Sabre Corporation has a trailing twelve months EPS of $-2.01.

Volume

Today’s last reported volume for Sabre Corporation is 6804560 which is 0.95% below its average volume of 6870120.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 8% and 52%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Sabre Corporation’s stock is considered to be overbought (>=80).

More news about Sabre Corporation.

7. LendingTree (TREE) – 9.51%

LendingTree, Inc., through its subsidiary, LT Intermediate Company, LLC, operates online consumer platform in the United States. It operates through three segments: Home, Consumer, and Insurance. The Home segment offers purchase mortgage, refinance mortgage, reverse mortgage, and home equity loans; lines of credit; and real estate brokerage services. The Consumer segment provides credit cards; personal, small business, student, and auto loans; deposit accounts; and other credit products, such as credit repair and debt settlement services. The Insurance segment includes information, tools, and access to insurance quote products, including home and automobile, through which consumers are matched with insurance lead aggregators to obtain insurance offers. In addition, the company offers QuoteWizard.com, a marketplace for insurance comparison; ValuePenguin, a personal finance website that offers consumers objective analysis on various financial topics from insurance to credit cards; and Stash, a consumer investing and banking platform that offers a suite of personal investment accounts, traditional and Roth IRAs, custodial investment accounts, and banking services, including checking accounts and debit cards with a Stock-Back rewards program. The company was formerly known as Tree.com, Inc. and changed its name to LendingTree, Inc. in January 2015. LendingTree, Inc. was incorporated in 1996 and is based in Charlotte, North Carolina.

NASDAQ ended the session with LendingTree jumping 9.51% to $18.54 on Wednesday while NASDAQ rose 1.28% to $12,500.57.

Earnings Per Share

As for profitability, LendingTree has a trailing twelve months EPS of $-12.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.24%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 29.2%, now sitting on 902.32M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LendingTree’s stock is considered to be overbought (>=80).

More news about LendingTree.

8. Marathon (MARA) – 9.41%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon jumping 9.41% to $10.12 on Wednesday, following the last session’s downward trend. NASDAQ jumped 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-6.27.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.77%, a negative 1.20%, and a positive 6.59%.

Marathon’s highest amplitude of average volatility was 7.34% (last week), 6.39% (last month), and 6.59% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 99.4% and 112.3%, respectively.

Volume

Today’s last reported volume for Marathon is 28702300 which is 15.01% below its average volume of 33773700.

Moving Average

Marathon’s value is way higher than its 50-day moving average of $8.65 and way higher than its 200-day moving average of $9.17.

More news about Marathon.

9. FuboTV (FUBO) – 9.15%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV rising 9.15% to $1.91 on Wednesday while NYSE jumped 1.22% to $15,313.92.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-1.84.

More news about FuboTV.

10. Summit Therapeutics plc (SMMT) – 9.09%

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

NASDAQ ended the session with Summit Therapeutics plc rising 9.09% to $1.68 on Wednesday while NASDAQ jumped 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Summit Therapeutics plc has a trailing twelve months EPS of $-0.33.

Yearly Top and Bottom Value

Summit Therapeutics plc’s stock is valued at $1.68 at 17:32 EST, way below its 52-week high of $5.78 and way higher than its 52-week low of $0.66.

Moving Average

Summit Therapeutics plc’s value is above its 50-day moving average of $1.64 and way under its 200-day moving average of $1.93.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Summit Therapeutics plc’s EBITDA is 3.18.

More news about Summit Therapeutics plc.

Losers Today

1. Qutoutiao (QTT) – -38.43%

Qutoutiao Inc. operates mobile platforms for the distribution, consumption, and sharing of light entertainment content in the People's Republic of China. The company operates Qutoutiao, a mobile application that aggregates articles and videos from content providers and presents real-time customized feeds to users, as well as provides online data processing and transaction processing services. It also offers Midu Novels, a mobile literature application that offers users free literature supported by advertising, as well as Midu Lite mobile literature application. The company was formerly known as Qtech Ltd. and changed its name to Qutoutiao Inc. in July 2018. Qutoutiao Inc. was founded in 2016 and is headquartered in Shanghai, China.

NASDAQ ended the session with Qutoutiao sliding 38.43% to $0.18 on Wednesday while NASDAQ jumped 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Qutoutiao has a trailing twelve months EPS of $-1.79.

Yearly Top and Bottom Value

Qutoutiao’s stock is valued at $0.18 at 17:32 EST, way below its 52-week high of $2.34 and way above its 52-week low of $0.15.

Volume

Today’s last reported volume for Qutoutiao is 4480230 which is 2584.96% above its average volume of 166864.

Moving Average

Qutoutiao’s value is way below its 50-day moving average of $0.50 and way below its 200-day moving average of $0.69.

Revenue Growth

Year-on-year quarterly revenue growth declined by 32.3%, now sitting on 4.34B for the twelve trailing months.

More news about Qutoutiao.

2. Predictive Oncology (POAI) – -19.88%

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

NASDAQ ended the session with Predictive Oncology dropping 19.88% to $2.74 on Wednesday, after four sequential sessions in a row of losses. NASDAQ rose 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Predictive Oncology has a trailing twelve months EPS of $-7.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -82.98%.

More news about Predictive Oncology.

3. Qurate Retail (QRTEA) – -12.04%

Qurate Retail, Inc., together with its subsidiaries, engages in the video and online commerce industries in North America, Europe, and Asia. The company markets and sells various consumer products primarily through merchandise-focused televised shopping programs, Internet, and mobile applications. It also operates as an online retailer offering women's, children's, and men's apparel; and other products, such as home, accessories, and beauty products through its app, mobile, and desktop applications. The company serves approximately 200 million homes worldwide. The company was formerly known as Liberty Interactive Corporation and changed its name to Qurate Retail, Inc. in April 2018. Qurate Retail, Inc. was founded in 1991 and is headquartered in Englewood, Colorado.

NASDAQ ended the session with Qurate Retail dropping 12.04% to $0.90 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ jumped 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Qurate Retail has a trailing twelve months EPS of $-5.97.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -135.86%.

Volume

Today’s last reported volume for Qurate Retail is 5416420 which is 32.08% below its average volume of 7975350.

Sales Growth

Qurate Retail’s sales growth is negative 5.6% for the ongoing quarter and negative 3.4% for the next.

Moving Average

Qurate Retail’s value is under its 50-day moving average of $0.92 and way under its 200-day moving average of $2.00.

More news about Qurate Retail.

4. VerifyMe (VRME) – -11.39%

VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.

NASDAQ ended the session with VerifyMe falling 11.39% to $1.40 on Wednesday, following the last session’s downward trend. NASDAQ rose 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, VerifyMe has a trailing twelve months EPS of $-1.71.

Volatility

VerifyMe’s last week, last month’s, and last quarter’s current intraday variation average was a negative 10.20%, a negative 0.38%, and a positive 4.11%.

VerifyMe’s highest amplitude of average volatility was 10.84% (last week), 4.79% (last month), and 4.11% (last quarter).

Moving Average

VerifyMe’s value is way under its 50-day moving average of $1.75 and under its 200-day moving average of $1.52.

Yearly Top and Bottom Value

VerifyMe’s stock is valued at $1.40 at 17:32 EST, way under its 52-week high of $2.82 and way above its 52-week low of $1.01.

More news about VerifyMe.

5. REGENXBIO (RGNX) – -9.17%

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

NASDAQ ended the session with REGENXBIO falling 9.17% to $19.72 on Wednesday while NASDAQ rose 1.28% to $12,500.57.

Earnings Per Share

As for profitability, REGENXBIO has a trailing twelve months EPS of $-6.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.81%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 13.9%, now sitting on 109.64M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 14.6% and 25.7%, respectively.

Yearly Top and Bottom Value

REGENXBIO’s stock is valued at $19.72 at 17:32 EST, way under its 52-week high of $35.73 and way above its 52-week low of $17.03.

More news about REGENXBIO.

6. Provident Bancorp (PVBC) – -9.08%

Provident Bancorp, Inc. operates as the bank holding company for The Provident Bank that provides various financial services to individuals and small businesses in the United States. It offers checking, term certificate, negotiable order of withdrawal, money market, and savings accounts, as well as certificates of deposit. The company also provides commercial real estate, multi-family residential real estate, commercial business, construction and land development, mortgage warehouse, one- to four-family residential, and consumer loans, as well as home equity loans and lines of credit; and invests in securities, and state and municipal bonds. As of December 31, 2021, it operated through its main office and six branch offices located in Amesbury and Newburyport, Massachusetts; and Bedford, Exeter, Portsmouth, and Seabrook, New Hampshire, as well as two loan production offices located in Boston, Massachusetts, and Ponte Vedra, Florida. The company was founded in 1828 and is headquartered in Amesbury, Massachusetts.

NASDAQ ended the session with Provident Bancorp dropping 9.08% to $7.41 on Wednesday while NASDAQ jumped 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Provident Bancorp has a trailing twelve months EPS of $-1.54.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.11%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Aug 10, 2022, the estimated forward annual dividend rate is 0.16 and the estimated forward annual dividend yield is 1.96%.

More news about Provident Bancorp.

7. Pieris Pharmaceuticals (PIRS) – -7.62%

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Pieris Pharmaceuticals sliding 7.62% to $0.80 on Wednesday while NASDAQ rose 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Pieris Pharmaceuticals has a trailing twelve months EPS of $-0.45.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 21.4% and a negative 46.2%, respectively.

More news about Pieris Pharmaceuticals.

8. Repare Therapeutics (RPTX) – -7.5%

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

NASDAQ ended the session with Repare Therapeutics dropping 7.5% to $9.38 on Wednesday while NASDAQ jumped 1.28% to $12,500.57.

Earnings Per Share

As for profitability, Repare Therapeutics has a trailing twelve months EPS of $-0.64.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Repare Therapeutics’s EBITDA is 0.7.

More news about Repare Therapeutics.

9. PLUS THERAPEUTICS (PSTV) – -7.09%

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

NASDAQ ended the session with PLUS THERAPEUTICS sliding 7.09% to $4.06 on Wednesday while NASDAQ jumped 1.28% to $12,500.57.

Earnings Per Share

As for profitability, PLUS THERAPEUTICS has a trailing twelve months EPS of $-9.88.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -242.11%.

Moving Average

PLUS THERAPEUTICS’s value is below its 50-day moving average of $4.14 and way under its 200-day moving average of $6.39.

More news about PLUS THERAPEUTICS.

10. Repay Holdings Corporation (RPAY) – -6.99%

Repay Holdings Corporation provides integrated payment processing solutions to industry-oriented markets. The company's payment processing solutions enable consumers and businesses to make payments using electronic payment methods. It also offers a range of solutions relating to electronic payment methods, including credit and debit processing, virtual credit card processing, automated clearing house (ACH) processing, enhanced ACH processing, and instant funding that are processed through its proprietary payment channels, such as Web-based, mobile application, text-to-pay, interactive voice response, and point of sale. In addition, the company provides payment processing solutions to customers primarily operating in the personal loans, automotive loans, receivables management, and business-to-business verticals. It sells its products through direct sales representatives and software integration partners. The company was founded in 2006 and is headquartered in Atlanta, Georgia.

NASDAQ ended the session with Repay Holdings Corporation dropping 6.99% to $6.65 on Wednesday, following the last session’s downward trend. NASDAQ rose 1.28% to $12,500.57, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Repay Holdings Corporation has a trailing twelve months EPS of $0.12.

PE Ratio

Repay Holdings Corporation has a trailing twelve months price to earnings ratio of 55.42. Meaning, the purchaser of the share is investing $55.42 for every dollar of annual earnings.

Yearly Top and Bottom Value

Repay Holdings Corporation’s stock is valued at $6.65 at 17:32 EST, way below its 52-week high of $14.61 and way higher than its 52-week low of $4.36.

More news about Repay Holdings Corporation.

Stay up to date with our winners and losers daily report